Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan.
Hirono M, Kobayashi M, Tsushima T, Obara W, Shinohara N, Ito K, Eto M, Takayama T, Fujii Y, Nishikido M, Kimura G, Kishida T, Takahashi M, Miyao N, Naya Y, Abe T, Fujioka T, Ito K, Naito S; Members of the Japanese Society of Renal Cancer. Hirono M, et al. Among authors: kimura g. BMC Cancer. 2013 Oct 2;13:447. doi: 10.1186/1471-2407-13-447. BMC Cancer. 2013. PMID: 24083566 Free PMC article.
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N, Nonomura N, Eto M, Kimura G, Minami H, Tokunaga S, Naito S. Shinohara N, et al. Among authors: kimura g. Ann Oncol. 2014 Feb;25(2):472-6. doi: 10.1093/annonc/mdt541. Epub 2013 Dec 18. Ann Oncol. 2014. PMID: 24351402 Free article. Clinical Trial.
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Kondo T, Nakazawa H, Oya M, Kimura G, Fujii Y, Hatano T, Kawata N, Kume H, Morita M, Nakajima K, Ohno Y, Okegawa T, Takahashi S, Wakumoto Y, Horie S, Yamaguchi R, Saito K, Murakami M. Kondo T, et al. Among authors: kimura g. Jpn J Clin Oncol. 2015 Mar;45(3):274-80. doi: 10.1093/jjco/hyu200. Epub 2014 Nov 23. Jpn J Clin Oncol. 2015. PMID: 25420693 Clinical Trial.
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A, Fujioka T, Kimura G, Shinohara N, Tatsugami K, Hinotsu S, Naito S; Japan RCC Trialist Collaborative Group (JRTCG) investigators. Eto M, et al. Among authors: kimura g. BMC Cancer. 2015 Oct 9;15:667. doi: 10.1186/s12885-015-1675-1. BMC Cancer. 2015. PMID: 26452347 Free PMC article. Clinical Trial.
Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
Oyama M, Sugiyama T, Nozawa M, Fujimoto K, Kishida T, Kimura G, Tokuda N, Hinotsu S, Shimozuma K, Akaza H, Ozono S. Oyama M, et al. Among authors: kimura g. Jpn J Clin Oncol. 2017 Jun 1;47(6):551-559. doi: 10.1093/jjco/hyw194. Jpn J Clin Oncol. 2017. PMID: 28334974 Free PMC article. Clinical Trial.
759 results